Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customersโ research, therapeutic and vaccine programs. This segmentโs business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segmentโs business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
์ข
๋ชฉ ์ฝ๋ MRVI
ํ์ฌ ์ด๋ฆMaravai LifeSciences Holdings Inc
์์ฅ์ผNov 20, 2020
CEOBrust (Bernd)
์ง์ ์570
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃNov 20
์ฃผ์10770 Wateridge Circle Suite 200
๋์SAN DIEGO
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ92121
์ ํ18585460004
์น์ฌ์ดํธhttps://www.maravai.com/
์ข
๋ชฉ ์ฝ๋ MRVI
์์ฅ์ผNov 20, 2020
CEOBrust (Bernd)
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์